Grasse BIOTECH

grassebiotech.fr

Grasse BIOTECH - Hotel of innovation companies and support of startups in the field of cosmetologies, biotechnologies, health, life sciences and scientific research and analysis activities of the Pays de Grasse, benefits from added value linked to a privileged project accelerator environment. On the ArômaGrasse Business Park where are hosted more than 15 companies such as: Perfume Cosmetic World, TOMCOS, SelectArôme ... mostly PASS (Perfumes, Aromas, Scents, Flavors). In connection with Espace Jacques-Louis Lions where are located: o the InnovaGrasse business incubator, o the University of Nice Sophia-Antipolis: training in fine chemistry master 2 FOQUAL, its students, professors and researchers in a place conducive to teaching and research (classrooms, laboratories, exchange rooms ...), o Technological and regulatory resources represented by the PASS Competitiveness Cluster and its partnership analytical chemistry platform, whose objective is to strengthen R & D by bringing researchers from the academic sector and the private sector together in a single location (certification and authentication). ingredients). In an already existing network of support for creation and innovation, Grasse BIOTECH thus makes it possible to cover the entire chain of support to businesses: from creation to their long-term presence on the territory of the Communauté d'Agglomération du Pays de Grasse. Grasse BIOTECH is funded with the support of the European Union with the European Regional Development Fund, the Regional Council PACA and the Departmental Council of the Alpes-Maritimes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CADENCE COMPLETES ACQUISITION OF OPENEYE SCIENTIFIC

Cadence | September 05, 2022

news image

Cadence Design Systems, Inc. announced today that it has completed the acquisition of OpenEye Scientific Software, Inc. The addition of OpenEye’s technologies and experienced team accelerates the Cadence® Intelligent System Design™ strategy by extending Cadence’s computational software core competency to molecular modeling and simulation that is targeted to life sciences. OpenEye, an industry leader in computational molecular design, has pioneered physics-bas...

Read More

MedTech

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

news image

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

news image

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

Industrial Impact

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

news image

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More
news image

Cell and Gene Therapy

CADENCE COMPLETES ACQUISITION OF OPENEYE SCIENTIFIC

Cadence | September 05, 2022

Cadence Design Systems, Inc. announced today that it has completed the acquisition of OpenEye Scientific Software, Inc. The addition of OpenEye’s technologies and experienced team accelerates the Cadence® Intelligent System Design™ strategy by extending Cadence’s computational software core competency to molecular modeling and simulation that is targeted to life sciences. OpenEye, an industry leader in computational molecular design, has pioneered physics-bas...

Read More
news image

MedTech

AVENGE BIO ANNOUNCES PEER-REVIEWED PUBLICATION ON PRECLINICAL PROOF-OF-CONCEPT FOR LOCOCYTE™ PLATFORM TECHNOLOGY IN MALIGNANT MESOTHELIOMA

Avenge Bio, Inc. | August 23, 2022

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

Read More
news image

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More
news image

Industrial Impact

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us